Exact Mass: 506.28863920000003
Exact Mass Matches: 506.28863920000003
Found 147 metabolites which its exact mass value is equals to given mass value 506.28863920000003
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits. (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits.
Ixabepilone
C27H42N2O5S (506.28142820000005)
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone lactam modification that
Bemcentinib
Chromogenic Substrate S-2266
11-O-acetyl-12-O-isovaleroyl-17beta-marsdenin|8-hydroxydrevogenin A
(1R,2E,4S,5R,6S,7E,10S,11S,12R)-5,6,10,18-tetraacetoxy-2,7-dolabelladiene|5,6,10,18-Tetraacetoxy-2,7-dolabelladiene
6alpha-O-(6-O-acetyl-beta-D-glucopyranosyl)-15,16-epoxycleroda-3,13(16),14-triene|salvigreside D
(20S,22R,24S,25R)-5alpha,6beta,14alpha,17beta,20-pentahydroxy-1-oxowitha-2-en-22,26-olide|24,25-dihydrowithanolide S
3beta,4beta,5alpha,6beta,27-pentahydroxy-1-oxo-with-24-enolide
digitoxigenin-3-O-beta-d-xyloside|digitoxigenyl beta-D-xyloside
14-O-alpha-L-rhamnopyranosyl-(2E,4E,7R,8E,10E,12E,14R)-7,9,13,17-tetramethyl-7,14-dihydroxy-2,4,8,10,12,16-octadecahexaenoic acid
Asn Val Phe Lys
Phe Gly Lys Arg
Phe Gly Arg Lys
Phe Lys Gly Arg
Phe Lys Asn Val
Phe Lys Arg Gly
Phe Lys Val Asn
Phe Asn Lys Val
Phe Asn Val Lys
Phe Arg Gly Lys
Phe Arg Lys Gly
Phe Val Lys Asn
Phe Val Asn Lys
Gly Phe Lys Arg
Gly Phe Arg Lys
Gly Lys Phe Arg
Gly Lys Arg Phe
Gly Arg Phe Lys
Gly Arg Lys Phe
Lys Phe Gly Arg
Lys Phe Asn Val
Lys Phe Arg Gly
Lys Phe Val Asn
Lys Gly Phe Arg
Lys Gly Arg Phe
Lys Lys Met Thr
C21H42N6O6S (506.28863920000003)
Lys Lys Thr Met
C21H42N6O6S (506.28863920000003)
Lys Met Lys Thr
C21H42N6O6S (506.28863920000003)
Lys Met Thr Lys
C21H42N6O6S (506.28863920000003)
Lys Asn Phe Val
Lys Asn Val Phe
Lys Arg Phe Gly
Lys Arg Gly Phe
Lys Thr Lys Met
C21H42N6O6S (506.28863920000003)
Lys Thr Met Lys
C21H42N6O6S (506.28863920000003)
Lys Val Phe Asn
Lys Val Asn Phe
Met Lys Lys Thr
C21H42N6O6S (506.28863920000003)
Met Lys Thr Lys
C21H42N6O6S (506.28863920000003)
Met Thr Lys Lys
C21H42N6O6S (506.28863920000003)
Asn Phe Lys Val
Asn Phe Val Lys
Asn Lys Phe Val
Asn Lys Val Phe
Asn Val Lys Phe
Arg Phe Gly Lys
Arg Phe Lys Gly
Arg Gly Phe Lys
Arg Gly Lys Phe
Arg Lys Phe Gly
Arg Lys Gly Phe
Thr Lys Lys Met
C21H42N6O6S (506.28863920000003)
Thr Lys Met Lys
C21H42N6O6S (506.28863920000003)
Thr Met Lys Lys
C21H42N6O6S (506.28863920000003)
Val Phe Lys Asn
Val Phe Asn Lys
Val Lys Phe Asn
Val Lys Asn Phe
Val Asn Phe Lys
Val Asn Lys Phe
Ixabepilone
C27H42N2O5S (506.28142820000005)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide
14-O-(alpha-L-rhamnopyranosyl)-7S,14R-dihydroxy-7,9,13,17-tetramethyl-2E,4E,8E,10E,12E,16E-octadecahexaenoic acid
Bemcentinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(1R)-1-(hydroxymethyl)-7-methoxy-2-[(3-methoxyphenyl)methyl]-N-propyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-2-[(3-methoxyphenyl)methyl]-N-propyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methyl-4-thiazolyl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
C27H42N2O5S (506.28142820000005)
2-[(1r,3ar,6r,7r,8r,12s,12as)-7,8,12-tris(acetyloxy)-3a,6,10-trimethyl-1h,2h,3h,6h,7h,8h,11h,12h,12ah-cyclopenta[11]annulen-1-yl]propan-2-yl acetate
(2e,4e,7s,8e,10e,12e,14r)-7-hydroxy-7,9,13,17-tetramethyl-14-{[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}octadeca-2,4,8,10,12,16-hexaenoic acid
(2r,3r,5r,6r,8s,9s,10r,11r)-8,10-dihydroxy-3,5,9,11-tetramethyl-2-[(2r)-3-oxopentan-2-yl]-8-[(1s)-1-(3,5,6-trimethyl-4-oxopyran-2-yl)ethyl]-1,7-dioxaspiro[5.5]undecan-4-one
6-(1-{3a,5,5a-trihydroxy-9a,11a-dimethyl-9-oxo-dodecahydrocyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
(6r)-6-[(1r)-1-[(1s,3ar,3br,5r,5ar,9ar,9br,11ar)-3a,5,5a-trihydroxy-9a,11a-dimethyl-9-oxo-dodecahydrocyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
15-(acetyloxy)-2-[2-(acetyloxy)ethylidene]-10-[(acetyloxy)methyl]-6,14-dimethylpentadeca-5,9,13-trien-1-yl acetate
8,10-dihydroxy-3,5,9,11-tetramethyl-2-(3-oxopentan-2-yl)-8-[1-(3,5,6-trimethyl-4-oxopyran-2-yl)ethyl]-1,7-dioxaspiro[5.5]undecan-4-one
(20r,22r)-5α,6β,14α,20,27-pentahydroxy-1-oxowitha-24-enolide
{"Ingredient_id": "HBIN003440","Ingredient_name": "(20r,22r)-5\u03b1,6\u03b2,14\u03b1,20,27-pentahydroxy-1-oxowitha-24-enolide","Alias": "NA","Ingredient_formula": "C28H42O8","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C(C)(C2CCC3(C2(CCC4C3CC(C5(C4(C(=O)CCC5)C)O)O)C)O)O)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16845","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}